Full Press Release Details
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong.
BIIB
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
Key Takeaway: “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
Price reaction · baseline $229.06 (2024-07-09 close) · hit after-hours · 1 other BIIB headline(s) in the window, move may be shared
day 0 close · peak
+1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis